Loss of cell cycle regulation due to disturbances in the cyclin pathway is common in advanced HR+/HER2– breast cancer and has led to development of treatments directed at this target through inhibition of CDK 4/6 [3]. This evidence concerns the gene ERBB2 and breast carcinoma.